No­vo rais­es 2023 out­look due to high­er than ex­pect­ed Ozem­pic and We­govy sales in the US

No­vo Nordisk is rais­ing its sales and op­er­at­ing prof­it es­ti­mates for the year thanks to its di­a­betes and an­ti-obe­si­ty semaglu­tide prod­ucts We­govy and Ozem­pic, the com­pa­ny an­nounced Fri­day ahead of its full re­port set to re­lease on Nov. 2.

In the first nine months of this year at cur­rent ex­change rates, No­vo’s sales in­creased by 33%, and op­er­at­ing prof­it in­creased by 37% af­ter raised ex­pec­ta­tions for Ozem­pic sales in the US and gross-to-net sales ad­just­ments for both Ozem­pic and We­govy in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER